These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6234387)

  • 1. Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. I.
    Anik ST; McRae G; Nerenberg C; Worden A; Foreman J; Hwang JY; Kushinsky S; Jones RE; Vickery B
    J Pharm Sci; 1984 May; 73(5):684-5. PubMed ID: 6234387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.
    Chu NI; Chan RL; Hama KM; Chaplin MD
    Drug Metab Dispos; 1985; 13(5):560-5. PubMed ID: 2865103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist.
    Chan RL; Chaplin MD
    Biochem Biophys Res Commun; 1985 Mar; 127(2):673-9. PubMed ID: 3156598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.
    Chan RL; Henzl MR; LePage ME; LaFargue J; Nerenberg CA; Anik S; Chaplin MD
    Clin Pharmacol Ther; 1988 Sep; 44(3):275-82. PubMed ID: 2970910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.
    Chan RL; Chaplin MD
    Drug Metab Dispos; 1985; 13(5):566-71. PubMed ID: 2865104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunoassay of nafarelin ([ 6-(3-(2-naphthyl)-D-alanine)]-luteinizing hormone-releasing hormone) in plasma or serum.
    Nerenberg C; Foreman J; Chu N; Chaplin MD; Kushinsky S
    Anal Biochem; 1984 Aug; 141(1):10-6. PubMed ID: 6238549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone analogs: update on new findings.
    Henzl MR
    Am J Obstet Gynecol; 1992 Feb; 166(2):757-61. PubMed ID: 1531579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in pulsatile release of neuropeptide-Y and luteinizing hormone (LH)-releasing hormone during the progesterone-induced LH surge in rhesus monkeys.
    Woller MJ; Terasawa E
    Endocrinology; 1994 Oct; 135(4):1679-86. PubMed ID: 7925132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of nafarelin in healthy volunteers.
    Chaplin MD
    Am J Obstet Gynecol; 1992 Feb; 166(2):762-5. PubMed ID: 1531580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats.
    Schmidt F; Sundaram K; Thau RB; Bardin CW
    Contraception; 1984 Mar; 29(3):283-9. PubMed ID: 6375959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of serum luteinizing hormone and testosterone with an inhibitory analog of luteinizing hormone-releasing hormone in adult male rhesus monkeys.
    Burgos-Briceño LA; Schally AV; Bartke A; Asch RH
    J Clin Endocrinol Metab; 1984 Oct; 59(4):601-7. PubMed ID: 6384248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin.
    Burns RA; Vitale K; Sanders LM
    J Microencapsul; 1990; 7(3):397-413. PubMed ID: 2143531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
    Schriock ED; Monroe SE; Martin MC; Henzl MR; Jaffe RB
    Fertil Steril; 1985 Jun; 43(6):844-50. PubMed ID: 3158549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres.
    Sanders LM; Kent JS; McRae GI; Vickery BH; Tice TR; Lewis DH
    J Pharm Sci; 1984 Sep; 73(9):1294-7. PubMed ID: 6238157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys.
    Sundaram K; Connell KG; Bardin CW; Samojlik E; Schally AV
    Endocrinology; 1982 Apr; 110(4):1308-14. PubMed ID: 6460610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.
    Penzias AS; Shamma FN; Gutmann JN; Jones EE; DeCherney AH; Lavy G
    Obstet Gynecol; 1992 May; 79(5 ( Pt 1)):739-42. PubMed ID: 1533022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of luteinizing hormone-releasing hormone on plasma cocaine levels in rhesus monkeys.
    Mendelson JH; Mello NK; Negus SS
    J Pharmacol Exp Ther; 1999 May; 289(2):791-9. PubMed ID: 10215654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.